D
David Warwick
Researcher at University of Southampton
Publications - 96
Citations - 2912
David Warwick is an academic researcher from University of Southampton. The author has contributed to research in topics: Collagenase clostridium histolyticum & Knee replacement. The author has an hindex of 29, co-authored 93 publications receiving 2736 citations. Previous affiliations of David Warwick include University of Bristol & Cambridge University Hospitals NHS Foundation Trust.
Papers
More filters
Journal ArticleDOI
Insufficient duration of venous thromboembolism prophylaxis after total hip or knee replacement when compared with the time course of thromboembolic events: findings from the Global Orthopaedic Registry.
David Warwick,Richard J. Friedman,Giancarlo Agnelli,E. Gil-Garay,Kirk Johnson,Gordon FitzGerald,Flavio Turibio +6 more
TL;DR: The risk of venous thromboembolism extends beyond the usual period of hospitalisation, while the duration of prophylaxis is often shorter than this, and practices should be re-assessed to ensure that patients receive appropriate durations of proplylaxis.
Journal ArticleDOI
Death and thromboembolic disease after total hip replacement. A series of 1162 cases with no routine chemical prophylaxis
TL;DR: The fatal PE rate after THR without routine chemical prophylaxis was low; a large discrepancy between the high DVT rate reported in clinical trials using universal screening venography and the symptomatic DVT rates shown in this study is shown.
Journal ArticleDOI
Comparison of the Use of a Foot Pump with the Use of Low-Molecular-Weight Heparin for the Prevention of Deep-Vein Thrombosis after Total Hip Replacement. A Prospective, Randomized Trial*
TL;DR: It is concluded that the foot pump is a suitable alternative to low-molecular-weight heparin for prophylaxis against thromboembolism after total hip replacement and that it produces fewer soft-tissue side effects.
Journal ArticleDOI
Prevention and Treatment of Venous Thromboembolism: International Consensus Statement (Guidelines according to scientific evidence)
Andrew N. Nicolaides,Jawed Fareed,Ajay K. Kakkar,Anthony J. Comerota,Samuel Z. Goldhaber,R D Hull,Kenneth A. Myers,M.M. Samama,John P. Fletcher,Evi Kalodiki,David Bergqvist,J. Bonnar,Joseph A. Caprini,Charles A. Carter,J. Conard,Bo Eklof,Ismail Elalamy,Grigoris T. Gerotziafas,George Geroulakos,Athanasios D. Giannoukas,Ian A. Greer,M. Griffin,Stavros K. Kakkos,M. R. Lassen,Gordon D.O. Lowe,A. Markel,Paolo Prandoni,Gary E. Raskob,Alex C. Spyropoulos,Alexander G.G. Turpie,Jeanine M. Walenga,David Warwick +31 more
TL;DR: All patients at moderate to high risk for the development of venous thrombo- embolism should receive prophylaxis, and the approaches of proven value include low-dose heparin, low molecular weight heparins, oral anticoagulants and intermittent pneumatic compression.
Journal Article
Prevention And Treatment Of Venous Thromboembolism : International Consensus Statement
Andrew N. Nicolaides,Jawed Fareed,Ajay K. Kakkar,Anthony J. Comerota,Samuel Z. Goldhaber,Russell D. Hull,Kenneth Myers,M. M. Samama,John P. Fletcher,Evi Kalodiki,David Bergqvist,J. Bonnar,Joseph A. Caprini,Cedric J. Carter,J. Conard,Bo Eklof,Ismail Elalamy,Grigoris T. Gerotziafas,George Geroulakos,Athanasios D. Giannoukas,Ian A. Greer,Maura Griffin,Stavros K. Kakkos,M. R. Lassen,Gordon D.O. Lowe,A. Markel,Paolo Prandoni,Gary E. Raskob,Alex C. Spyropoulos,Alexander G.G. Turpie,Jeanine M. Walenga,David Warwick +31 more
TL;DR: The aim of this document is to provide a clear and concise account of the evidence regarding efficacy or harm for various methods available to prevent and manage venous thromboembolism (VTE).